COVID-19 in patients with lung cancer receiving immunotherapy. A report from an spanish academic center

Viñal, David Gutierrez Laura Villamayor Julia Higuera Oliver Dario Sanchez Cabrero De Castro Javier

482 Table 1Clinical characteristicsECOG PS, Eastern Cooperative Oncology Group Performance Status;NSCLC, Non-Small-Cell Lung Cancer;SCLC, Small-Cell Lung Cancer;CT, chemotherapy;ICI, immune checkpoint inhibitors;TKI, tyrosine-kinase inhibitorsAbstract 482 Figure 1Overall survival. Overall survival in patients with lung cancer treated with immunotherapy vs other therapies[Figure omitted. See PDF]ConclusionsWe found that patients with lung cancer represent an extremely vulnerable population, with a poor prognosis after COVID-19 diagnosis. Treatment with immunotherapy may also be considered a risk factor. Emphasis on prevention and treatment based on evidence-based medicine is crucial in our daily practice.AcknowledgementsThis work has not been supported by public grants or financial support. No sources of funding were used to assist in the preparation of this manuscriptEthics ApprovalThe study was approved by Hospital Universitario La Paz Institution’s Ethics Board, approval number PI-4147ReferencesChen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7Giannakoulis VG, Papoutsi E, Siempos II. Effect of Cancer on Clinical Outcomes of Patients With COVID-19: a meta-analysis of patient data. JCO Glob Oncol 2020;6:799–808. doi:10.1200/GO.20.00225Lee LYW, Cazier JB, Starkey T, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 2020;395(10241):1919–1926. doi:10.1016/S0140-6736(20)31173-9